ST Renfu announced that Yichang Renfu, a holding subsidiary of the company, has received a marketing license approval letter for the marketing of sodium shugeng glucose injection approved by the UK Medicines and Health Products Regulatory Authority. The approved indications are antagonizing neuromuscular block induced by rocuronium bromide or vecuronium bromide in adults, and routine antagonism of rocuronium-induced block in pediatric patients from birth to 17 years old. The license is valid for 5 years. The project has invested a total of about 13 million yuan in R&D. After the product is approved, it can be sold in the UK, which will have a positive impact on the company's international business expansion. The actual sales situation is uncertain due to multiple factors.

ST Renfu announced that Yichang Renfu, a holding subsidiary of the company, has received a marketing license approval letter for the marketing of sodium shugeng glucose injection approved by the UK Drug and Health Products Regulatory Authority. The approved indications are antagonizing neuromuscular block induced by rocuronium bromide or vecuronium bromide in adults, and routine antagonism of rocuronium-induced block in pediatric patients from birth to 17 years old. The license is valid for 5 years. The project has invested a total of about 13 million yuan in R&D. After the product is approved, it can be sold in the UK, which will have a positive impact on the company's international business expansion. The actual sales situation is uncertain due to multiple factors.